ETOPOPHOS® 100 mg

DRUG2 trials

Sponsors

Prinses Maxima Centrum voor Kinderoncologie B.V., GWT-Tud GmbH

Conditions

Acute Myeloid LeukemiaAdult patients with relapsed or primary refractory DLBCL

Phase 3

CHIP-AML22 Master protocol: An open label complex clinical trial in newly diagnosed pediatric de novo AML patients – a study by the NOPHO-DB-SHIP consortium Master Protocol

RecruitingCTIS2023-504999-25-00

Prinses Maxima Centrum voor Kinderoncologie B.V.Acute Myeloid Leukemia

Start: 2023-07-14Target: 675Updated: 2025-08-14

An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)

CompletedCTIS2023-508259-38-00

GWT-Tud GmbHAdult patients with relapsed or primary refractory DLBCL

Start: 2021-04-29End: 2025-12-19Target: 302Updated: 2025-11-05